Prognostic determinants in patients with uterine and ovarian carcinosarcoma

Journal of Reproductive Medicine

Volumn 58, Issue 7-8, 2013, Pages 297-304

  Rauh Hain, J Alejandro ^a,b   Shoni, Melina ^a,b   Schorge, John O ^a,b   Goodman, Annekathryn ^a,b   Horowitz, Neil S ^a,b   del Carmen, Marcela G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinosarcoma; Ovarian cancer; Uterine cancer

Indexed keywords

PLATINUM COMPLEX;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOSARCOMA; COMPARATIVE STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARIAN CARCINOSARCOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME; UTERINE CARCINOSARCOMA; UTERUS CARCINOMA;

AGED; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 84881181097     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Inthasorn P, Carter J, Valmadre S, et al: Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348-353
2. Tate Thigpen J, Blessing JA, DeGeest K, et al: Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336-339
3. Mano MS, Rosa DD, Azambuja E, et al: Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17:316-324
4. Clarke TJ: Histogenesis of ovarian malignant mixed mesodermal tumours. J Clin Pathol 1990;43:287-290
5. Kounelis S, Jones MW, Papadaki H, et al: Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: Comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-87
6. Mayall F, Rutty K, Campbell F, et al: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994;24:211-214
7. Silverberg SG, Major FJ, Blessing JA, et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19
8. Rauh-Hain JA, Growdon WB, Rodriguez N, et al: Carcinosarcoma of the ovary: An updated series. Gynecol Oncol 2011;121:477-481
9. Yamada SD, Burger RA, Brewster WR, et al: Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782-2786
10. Cantrell LA, Van Le L: Carcinosarcoma of the ovary: A review. Obstet Gynecol Surv 2009;64:673-680
11. Barholtz-Sloan J, Bryant C, Morris R, et al: Survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93:506-512
12. Rutledge TL, Gold MA, McMeekin DS, et al: Carcinosarcoma of the ovary: A case series. Gynecol Oncol 2006;100:128-132
13. Zorn KK, Bonome T, Gangi L, et al: Gene expression profiles of serous, endometrioid and clear cell subtypes of ovarian and endometrial cancer. Clin Res 2005;11:6422-6430
14. Growdon WB, Roussel BN, Scialabba VL, et al: Tissuespecific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011;121:212-217
15. Creasman WT: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009; 105:103-104
16. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
17. Bookman MA: Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy. Oncologist 1999;4:87-94
18. Markman M: Recurrence within 6 months of platinum therapy: An adequate definition of "platinum-refractory" ovarian cancer? Gynecol Oncol 1998;69:91-92
19. Garg G, Shah JP, Kumar S, et al: Ovarian and uterine carcinosarcomas: A comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010;20:888-894
20. Jonson AL, Bliss RL, Truskinovsky A, et al: Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol 2006;100:561-564
21. Sreenan JJ, Hart WR: Carcinosarcomas of the female genital tract. Am J Surg Pathol 1995;19:666-674